

ARIZONA'S
BIOSCIENCE
ROADMAP

2014-2025

Advancing the
Biosciences and
Improving Health
Outcomes

Mitch Horowitz

Principal and Managing Director

TEconomy Partners, LLC

March 29-31, 2016

WHAT IS THE ROADMAP?

Arizona's Bioscience Roadmap:

- 20-year plan to bring Arizona to competitiveness in bioscience
- Commissioned by the Flinn Foundation; compiled by Battelle, tracked by TEConomy Partners
- Goals: economic strength and diversity, access to health innovations for Arizonans
- Focused on leveraging research strengths, building critical mass of firms

FIRST DECADE: 2002-2012

Outcomes:

- Substantial statewide development
- Industry grew rapidly, even during Great Recession
- Research funding grew, rate slowed in final years
- Risk capital dropped precipitously after 2002
- Progress on all 19 Roadmap actions, substantial progress on 10
- AZ: top emerging bio state with “collaborative gene”

SECOND “DECADE”: 2013-2025

Vision:

“Arizona is **globally competitive** and a **national leader** in the biosciences in such fields as precision medicine, cancer, neurosciences, bioengineering, diagnostics, and agricultural biotechnology.

“It excels in offering a **deep talent base**, a critical mass of **entrepreneurs and enterprises**, and **clinical excellence** to turn discovery into firms, products, and talent.”

17 Strategies to Achieve 5 Goals:

- Provide direction for Roadmap implementation
- To be re-examined at midpoint of Second Decade Roadmap

77 Potential Actions to Implement Strategies:

- Prioritized based on feasibility, impact
- Designed to evolve
- Available at www.flinn.org


WHAT ARE THE BIOSCIENCES?

- Agricultural Feedstock and Chemicals
- Bioscience-Related Distribution
- Drugs, Pharmaceuticals and Diagnostics
- Medical Devices and Equipment
- Research, Testing and Medical Labs
- Hospitals




METRIC: JOBS

Arizona Bioscience Jobs Composition




METRIC: JOBS

AZ & U.S. Bioscience Employment: 2002-14



Non-Hospital Bioscience Employment: 2002-14



METRIC: JOBS

Employment Across Business Cycles

| Industry Subsector | Economic Expansion | | Recession | | Recovery/Expansion | |
|---|----------------------|------------------------|----------------------|------------------------|----------------------|------------------------|
| | AZ Change 2002-07 | U.S. Change 2002-07 | AZ Change 2007-09 | U.S. Change 2007-09 | AZ Change 2009-14 | U.S. Change 2009-14 |
| Total Private Sector | 19.8% | 6.0% | -11.3% | -6.2% | 7.7% | 7.8% |
| Total Biosciences | 22.2% | 7.8% | 6.8% | 2.5% | 14.8% | 2.8% |
| Total Non-Hospital Biosciences | 19.0% | 5.8% | 6.2% | -0.6% | 16.9% | 2.7% |
| Agricultural Feedstock & Chemicals | 20.0% | -6.8% | -1.7% | 2.1% | 9.4% | 0.6% |
| Bioscience-related Distribution | 14.4% | 7.8% | 2.0% | -3.3% | -4.8% | 1.8% |
| Drugs & Pharmaceuticals | 17.1% | -0.1% | -8.7% | -4.8% | 84.5% | -3.4% |
| Medical Devices & Equipment | 33.4% | 1.9% | 13.8% | 0.6% | 36.9% | 1.1% |
| Research, Testing, & Medical Laboratories | 17.5% | 14.6% | 10.9% | 3.8% | 21.7% | 9.3% |
| Hospitals | 23.1% | 8.6% | 7.0% | 3.7% | 14.2% | 2.8% |

INDUSTRY PROFILE

| INDUSTRY SUBSECTOR | JOBS | ESTABLISHMENTS | AVERAGE WAGES | LOCATION QUOTIENT |
|---------------------------------------|----------------|----------------|-----------------|-------------------|
| Agricultural Feedstock & Chemicals | 595 | 14 | \$53,324 | 0.41 |
| Bioscience-Related Distribution | 8,021 | 755 | \$94,975 | 0.95 |
| Drugs & Pharmaceuticals | 1,867 | 47 | \$54,289 | 0.34 |
| Medical Devices & Equipment | 6,082 | 107 | \$67,354 | 0.94 |
| Research, Testing & Medical Labs | 7,475 | 362 | \$71,059 | 0.82 |
| Hospitals | 86,370 | 127 | \$57,777 | 0.98 |
| Total Non-Hospital Biosciences | 24,040 | 1,284 | \$76,360 | 0.78 |
| TOTAL BIOSCIENCES | 110,410 | 1,411 | \$61,823 | 0.92 |

¹ Industry data are from 2014.

² Location quotient is the level of industry concentration relative to the nation; 1.0 represents the national average.

Source: TEconomy Partners LLC analysis of Bureau of Labor Statistics, QCEW data from IMPLAN Group LLC

METRIC: WAGES

Bioscience Wage Growth: 2013-14

| Major AZ Industries & Subsectors | Avg. Annual Wages, 2013 | Avg. Annual Wages, 2014 | Change 2013-14 |
|---|-------------------------|-------------------------|----------------|
| Bioscience-related Distribution | \$95,642 | \$94,975 | -1% |
| Total Non-Hospital Biosciences | \$74,881 | \$76,360 | 2% |
| Research, Testing, & Medical Laboratories | \$66,094 | \$71,059 | 8% |
| Medical Devices & Equipment | \$65,345 | \$67,354 | 3% |
| Total Biosciences | \$60,864 | \$61,823 | 2% |
| Hospitals | \$56,891 | \$57,777 | 2% |
| Drugs & Pharmaceuticals | \$51,873 | \$54,289 | 5% |
| Agricultural Feedstock & Chemicals | \$48,503 | \$53,324 | 10% |
| Total Private Sector | \$45,503 | \$46,514 | 2% |

Distribution of:

- Agricultural chemicals/seeds
- Biomedical equipment/supplies
- Drugs/pharmaceuticals

Specializes in:

- Cold storage
- Product monitoring
- Automated pharmaceutical distribution systems


In Arizona:

- Jobs: 8,021 (33%)*
- Establishments: 755 (59%)*
- Location quotient: 0.95
- Average Wages: \$94,975

** Percentage among non-hospital subsectors*


METRIC: ESTABLISHMENTS

AZ & U.S. Bioscience Establishments: 2002-14




METRIC: ESTABLISHMENTS

Non-Hospital Bioscience Establishments: 2002-14




METRIC: ESTABLISHMENTS

Non-Distribution Bioscience Establishments: 2002-14




METRIC: ESTABLISHMENTS

Non-Distribution/Hospital Bio Establishments: 2002-14



INNOVATION ECOSYSTEM



METRIC: BIOSCIENCE R&D

AZ Academic R&D in Bio-Related Fields: FY 2014


- Total bioscience-related R&D: \$451M
- Total non-bioscience-related R&D: \$536M

U.S. Academic R&D in Bio-Related Fields: FY 2014

- Total bioscience-related R&D: \$41.7B
- Total non-bioscience-related R&D: \$22B

METRIC: BIOSCIENCE R&D


Distribution of Academic R&D in Bio-Related Fields



(Figures in \$ Millions)


METRIC: BIOSCIENCE R&D

AZ & U.S. Bioscience Academic R&D: 2002-14




METRIC: NIH

AZ & U.S. NIH Funding: 2002-15




METRIC: NIH

AZ & U.S. NIH Funding: 2002-15




METRIC: NIH

NIH Grants, Funding Growth: 2002-15




AZ NIH Funding Distribution: FY 2015



METRIC: NIH

Arizona Share of NIH Support




AZ University Bioscience Tech Transfer: 2014-15

| Key Tech-Transfer Metrics | Total 2014-2015 | Growth 2012-13 to 2014-15 | Bio Share of Tech Transfer 2014-15 |
|--|-----------------|---------------------------|------------------------------------|
| Bioscience R&D Expenditures | \$736.4M | n/a | 34.2% |
| Invention Disclosures Received | 521 | 54.1% | 53.0% |
| Total U.S. Patent Applications Filed | 397 | 21.0% | 54.8% |
| U.S. Patents Issued | 81 | 72.3% | 44.0% |
| Licenses & Options Executed | 121 | 26.0% | 37.0% |
| Adjusted Gross License Income Received | \$7.7M | 30.9% | 77.2% |
| Bioscience Startups from University IP | 21 | 23.5% | 42.9% |


METRIC: VENTURE CAPITAL

AZ Share of U.S. Bio Venture Capital: 2002-15




METRIC: VENTURE CAPITAL

AZ & U.S. Bio Venture Capital: 2002-15



METRIC: VENTURE CAPITAL

AZ & U.S. Venture Capital by Stage



METRIC: VENTURE CAPITAL

AZ & U.S. Bio Share of Venture Capital, 2002-15*

| Metric | ARIZONA | | | | U.S. | | |
|--|---------|----------|--------------------------|-----------------------------|-----------|-----------|----------------------------|
| | Bio VC | Total VC | Bio Share of Total AZ VC | AZ Bio Share of U.S. Bio VC | Bio VC | Total VC | Bio Share of Total U.S. VC |
| Number of Deals | 126 | 479 | 26% | 0.71% | 17,833 | 67,147 | 27% |
| Number of Individual Companies Invested in | 40 | 168 | 24% | 0.78% | 5,104 | 23,613 | 22% |
| Investment (in \$ Millions) | \$716 | \$3,687 | 19% | 0.50% | \$142,964 | \$567,345 | 25% |


Source: Thomson Reuters Thomson One Database with TEconomy Partners Calculations

* Because the Thomson One Database is continually updated, VC data presented may not correspond exactly to data in previous iterations of this report.


METRIC: VENTURE CAPITAL

Share of VC Investments by Bio-Related Industry


Arizona



U.S.



REGIONAL BIO STRENGTHS



FLAGSTAFF METRO AREA

| Key Bioscience Subsector | Establishments, Employment Level & Concentration (2014) | Regional Strengths/ Highlights |
|-----------------------------|---|---|
| Medical Devices & Equipment | Establishments: 2 Employed: 2,321 Employment Growth (02-14): 160% Location Quotient: 17.94 | Flagstaff remains highly specialized in medical devices, at almost 18 times the average employment concentration of the nation. |
| Hospitals | Establishments: 2 Employed: 3,566 Employment Growth (02-14): 44% Location Quotient: 1.96 | The hospital subsector is a large employer in Flagstaff, with over 3,500 workers in 2014. It is also growing quickly, with employment increasing by 44% from 2002-14. |

PHOENIX-MESA-SCOTTSDALE

| Key Bioscience Subsector | Establishments, Employment Level & Concentration (2014) | Regional Strengths/ Highlights |
|--|---|---|
| Research, Testing & Medical Laboratories | Establishments: 266 Employed: 5,974 Employment Growth (02-14): 63% Location Quotient: 0.88 | Employment in research, testing & medical labs approaching 6,000 in metro Phoenix, with substantial growth of 63% from 2002-14. |
| Bioscience-related Distribution | Establishments: 616 Employed: 6,913 Employment Growth (02-14): 14% Location Quotient: 1.11 | Bioscience-related distribution in the Phoenix area is largest non-hospital subsector in metro Phoenix, 11% more concentrated than the U.S. |
| Hospitals | Establishments: 84 Employed: 54,801 Employment Growth (02-14): 53% Location Quotient: 0.83 | Hospitals remain the predominant subsector for bioscience employment in metro Phoenix, with 53% growth over 2002-14 period. |

TUCSON METRO AREA

| Key Bioscience Subsector | Establishments, Employment Level & Concentration (2014) | Regional Strengths/ Highlights |
|--|---|---|
| Research, Testing & Medical Laboratories | Establishments: 65 Employed: 1,167 Employment Growth (02-14): 36% Location Quotient: 0.97 | The research, testing & medical labs subsector in the Tucson area increased employment by 36% over the 2002-14 period. |
| Hospitals | Establishments: 13 Employed: 16,243 Employment Growth (02-14): 31% Location Quotient: 1.39 | Tucson has a large, growing, and specialized hospital subsector with 39% higher employment concentration than the nation. |
| Medical Devices & Equipment | Establishments: 23 Employed: 1,082 Employment Growth (02-14): 88% Location Quotient: 1.30 | Tucson's medical devices & equipment subsector grew by 88% over the 2002-14 period, 30% more highly concentrated than the nation. |

Arizona's Targets for 2025:

- 1. Risk Capital:** Reach market share equal to population (\$100-125M annually in bioscience venture capital, \$25-40M in pre-seed/seed).
- 2. Research:** Reach national performance level for bioscience research revenue at research-performing institutions (\$782M annually).
- 3. Infrastructure:** Invest \$500-750M over 10 years in academic research infrastructure.
- 4. Anchors:** Add 5-7 cornerstone bio institutions.
- 5. Regional Connections:** Strengthen ties with economic partners beyond Arizona to support industry maturation and specialization.

Arizona's Challenge

To achieve Arizona's targets for 2025, it must **enhance research** that stimulates **new venture formation** and can **attract capital**—increasing the likelihood that **new anchors** will emerge in the state.

Increasing industry/academia collaborations:

Fast pace of basic scientific insights into biological processes informs advances in medical discovery.

Key BIO Report:

Advancing Translational Research for Biomedical Innovation: Measuring Industry-Academic Connections

- 23% increase over 10 years in joint industry-academic publications in biomedical-related fields;
- 81.5% increase over 10 years in industry patents citing academic research informing innovations.



A “Real-World” Context of Developments to Advance Translational Research



Basic & Applied Research

Multi-Institutional/
Multi-Company
Collaborations

Open Innovation
Collaborations

Technology Development

Partnerships of
Clinicians-Engineers-
Scientists

New Venture
Development
Organizations

Clinical Trials

Regional Clinical Trials
Consortia

CRO-CTSI
Partnerships

Centralized Patient
Registry

New Product Launch

Experimental
Therapeutics Centers

Advanced
Biomanufacturing
Centers

Building new research anchors with industry:

Indiana Biosciences Research Institute

- New public-private partnership launched in 2013
- \$50M initial investment: \$25M state investment matched by industry and foundations
- Focus on attracting 8-12 leading research teams to Indiana to collaborate and work alongside industry research-and-development teams
- Initial focus on metabolic health and nutrition
- Industry members include Lilly, Roche, Dow AgroSciences, Cook, and Biomet/Zimmer
- Anchoring new innovation district in Indy – “16 Tech”

EMERGING BEST PRACTICES

Creating a signature shared-use facility to further commercialization:

Oregon Translational Research and Development Institute (OTRADI)

- Launched as a Signature Research Center of Oregon Inc. in 2007
- Focus on high-throughput and high-content new drug discovery
- Significant activities:
 - 35 Oregon company members using facilities
 - Partnerships with 150+ Oregon university researchers to advance medical discovery
- Recently added a wet-lab incubator facility for bio start-ups

Forming mechanism to create new bio ventures:

GRA Ventures

- Started in 2002 to develop companies from university research
- Multi-phased approach: Identify promising technologies, conduct due diligence, support proof-of-concept, and fund venture start-up
- Record of success:
 - 100 university-based companies assisted, generating \$500M in private-equity investments and employment of 600
 - New \$20M GRA Venture Fund, LLC. focused on Series A early-stage investments in 2009—state commitment of \$7.5M in capital investment and income tax credits for investors of 25 percent

CONTACT

Mitch Horowitz

Principal and Managing Director

TEconomy Partners, LLC

(240) 462-5456

horowitzm@teconomypartners.com